Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)

Creative Commons License

Gibson C. M., Chi G., Halaby R., Korjian S., Daaboul Y., Jain P., ...More

CIRCULATION, vol.135, no.7, pp.648-655, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 135 Issue: 7
  • Publication Date: 2017
  • Doi Number: 10.1161/circulationaha.116.025427
  • Journal Name: CIRCULATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.648-655
  • Keywords: anticoagulants, cardiology, cardiovascular diseases, intracranial hemorrhages, stroke, thrombosis, WARFARIN, OUTCOMES, CARE
  • Hacettepe University Affiliated: Yes


BACKGROUND: Stroke is a morbid and potentially mortal complication among patients hospitalized with acute medical illness. The potential of extended-duration thromboprophylaxis with the factor Xa inhibitor betrixaban to reduce the risk of stroke compared with standard-dose enoxaparin in this population was assessed in this retrospective APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).